Certara, Princeton, New Jersey, USA. Centre for Applied Pharmacokinetic Research, University of Manchester, Manchester, UK. Search for more papers by this author

Certara, Blades Enterprise Centre, Sheffield, UK Correspondence: A. Rostami‐Hodjegan ( amin.rostami@manchester.ac.uk ) Search for more papers by this author First published: 12 October 2017

See insights on Certara including office locations, competitors, revenue, financials, executives, subsidiaries and more at Craft. Certara is a leading decision support technology and consulting organization committed to optimizing drug development and improving health outcomes. Certara’s solutions, which span drug discovery through patient care, use the most scientifically-advanced modeling and simulation technologies and regulatory strategies to increase the probability of regulatory and commercial success. By: Amin Rostami Professor Rostami is the Senior Vice President of Research & Development and Chief Scientific Officer at Certara. His mission is to ensure that the latest scientific advances in the field of biosimulation are incorporated into all of the drug development efforts by various pharmaceutical companies.

Amin rostami certara

Professor Rostami is the Senior Vice President of Research & Development and Chief Scientific Officer at Certara. His mission is to insure that the latest scientific advances in the field of biosimulation are incorporated into all of the drug development efforts by various pharmaceutical companies. amin.rostami@manchester.ac.uk; Centre for Applied Pharmacokinetic Research (CAPKR), University of Manchester, UK, and Certara, Princeton, New Jersey, USA. Correspondence: Amin Rostami‐Hodjegan (amin.rostami@manchester.ac.uk)Search for more papers by this author Amin Rostami-Hochaghan (Participant) Impact : Cultural impacts, Economic impacts, Health impacts, Political impacts, Technological impacts Dosing for groups of patients who were not served previously by conventional drug information. amin.rostami@manchester.ac.uk; Centre for Applied Pharmacokinetic Research, University of Manchester, Manchester, UK. Certara (Simcyp Division), Sheffield, UK. Correspondence: Jashvant D. Unadkat (jash@uw.edu) and Amin Rostami‐Hodjegan (amin.rostami@manchester.ac.uk)Search for more papers by this author Amin Rostami - DaryaArrangement: Mehran KhalesiMix & Mastering: Amin RostamiMusic: Amin RostamiLyrics: Mehrzad Amirkhani Principal Scientist at Simcyp, Certara. Simcyp, Certara Experience.

Executive Profiles. William F. Feehery Chief Executive Officer. Robert Aspbury President, Simcyp.

Amin Rostami. Chief Scientific Officer. He joined Certara in 2012 as a co-founder of Simcyp Limited (a University of Sheffield spin-off which was acquired by Certara), Amin is also a Professor of Systems Pharmacology and the Director of the Centre for Applied Pharmacokinetic Research (CAPKR)

Mr. Leif E. Pedersen, Pres of Software, 295.4k, N/A, 1965. Mr. Andrew Schemick, Chief Financial Officer, N/A, N/A, N/A. Prof. Amin Rostami PharmD, Ph.D., FCP Amin is a Professor of Systems Pharmacology at the Centre for Applied at Simcyp Limited (a Certara Company), Amin leads a team of over 30 scientists in.

Amin Rostami. Chief Scientific Officer. He joined Certara in 2012 as a co-founder of Simcyp Limited (a University of Sheffield spin-off which was acquired by Certara), Amin is also a Professor of Systems Pharmacology and the Director of the Centre for Applied Pharmacokinetic Research (CAPKR)

Acknowledgements • Prof Amin Rostami-Hodjegan • Dr Masoud Jamei • Dr Khaled Abduljalil To address that gap, MIDD software developer Certara L.P. genes by sequencing RNA in plasma exosomes.

Amin Rostami‐Hodjegan. Certara, Princeton, Correspondence: Thomas M. Polasek (tom.polasek@certara.com) Search for more papers by this author.
Apn malmö stad

He is an original thinker, who can envision how to combine disciplines to disrupt the status quo and improve the drug development paradigm, said Certara Chief Executive Officer The Simcyp™ division was founded in 2001 by Professors Geoff Tucker and Amin Rostami-Hodjegan as a spin-out company from the University of Sheffield, UK. Simcyp was acquired by Certara in 2012 and has experienced dynamic growth, employing over 130 people including scientists, software developers, Rostami is recognized for his scientific leadership, original thinking, and commitment to knowledge sharing with his colleagues and students PRINCETON, NJ – Jan. 29, 2015 – Certara®, the global biosimulation technology-enabled drug development and drug safety consulting company, today announced that it has promoted Amin Rostami, Pharm.D., Ph.D. to senior vice president (SVP) of R&D and Amin Rostami-Hodjegan is Chief Scientific Officer at Certara USA, Inc. View Amin Rostami-Hodjegan’s professional profile on Relationship Science, the database of decision makers. PRINCETON, NJ – Jan. 29, 2015 – Certara®, the global biosimulation technology-enabled drug development and drug safety consulting company, today announced that it has promoted Amin Rostami ST. LOUIS, MO - Feb 26, 2014 - Certara™, a leading provider of software and scientific consulting services to improve productivity and decision-making from drug discovery through drug development, today announced that Amin Rostami, Pharm.D., Ph.D., FCP, the company's vice president of research and development (R&D), has been selected as a Fellow of the American Association of Pharmaceutical 5 Simcyp Limited (a Certara Company), Blades Enterprise Centre, John Street, Sheffield S2 4SU, UK; Centre for Applied Pharmacokinetic Research, School of Pharmacy and Pharmaceutical Sciences, University of Manchester, Manchester, UK. Electronic address: amin.rostami@manchester.ac.uk. “Certara recognized several years ago that model-informed drug development (MIDD) could also provide tremendous value if used by healthcare providers (HCPs) to determine the optimal drug dose for individual patients in the clinic,” said Certara Chief Scientific Officer Professor Amin Rostami.

Slide Courtesy - Amin Rostami Hodjegan (Uni Manchester) Departement of Chemistry, Faculty of Science, University of Kurdistan, Sanandaj, Iran - ‪‪Cited by 2035‬‬ - ‪Heterogeneous Catalyst‬ - ‪Biocatalyst and‬ Melinda Gates Foundation, Dr Jacqueline Barry, Catapult, Prof Stefan James, Uppsala University and Prof Amin Rostami, University of Manchester/Certara. Certara Lecturer in Model-Based Precision Dosing wall metabolism", Supervisory team: Dr Amin Rostami, Professor of Systems Pharmacology and Dr Darren Rostami-Hodjegan, Amin. Univ Manchester, Manchester Pharm Sch, Ctr Appl Pharmacokinet Res, Manchester M13 9PT, Lancs, England.;Certara, Blades Rostami-Hodjegan, Amin Leiden Acad Ctr Drug Res, Leiden, Netherlands.;Certara QSP, Canterbury, Certara Strateg Consulting, Montreal, PQ, Canada. Rostami-Hodjegan, Amin.
Why do i get dizzy standing up

verksamhetschef engelska
hur kommer man fram till vårdcentralen getingen i lund
laholms el
migrationsverket lifos irak
se när bilen ska besiktigas

At Certara, Amin Rostami has 12 colleagues who can be contacted including William Feehery (CEO), Eric Liu (Director)… Industry Colleagues. In the Pharmaceuticals industry, Amin Rostami has 19,287 colleagues in 2,058 companies located in 74 countries

4Office of A Rostami-Hodjegan is an employee of the University of Manchester for 50% of his working hours and Certara for 50% of his working hours. The authors have Principal Scientist at Simcyp, Certara. Simcyp, Certara Experience. Simcyp, Certara Graphic Theresa Cain; Helen Humphries; Amin Rostami-Hodjegan. Mr. Leif E. Pedersen, Pres of Software, 295.4k, N/A, 1965. Mr. Andrew Schemick, Chief Financial Officer, N/A, N/A, N/A. Prof.

Professor Rostami is the Senior Vice President of Research & Development and Chief Scientific Officer at Certara. His mission is to ensure that the latest scientific advances in the field of biosimulation are incorporated into all of the drug development efforts by various pharmaceutical companies.

Simcyp joined with Certara in 2012 and has experienced dynamic growth, delivering groundbre Amin Rostami-Hodjegan, Masoud Jamei, & Thomas Polasek. 2 www.certara.com Physiologically-based pharmacokinetic modeling and simulation (PBPK M&S) •The authors thank Dr .Bob Powel and Prof Amin Rostami for their great help in the project design. Thank Dr. Pavan Vajjah for his support in SimCYP simulation. Thank Dr. Ao Peng for his work in the bioassay. 0.00E+00 2.00E+00 4.00E+00 6.00E+00 8.00E+00 1.00E+01 1.20E+01 1.40E+01 0 24 48 72 96 120 144 168 192 216 240 (mg/L) Time (h) Biography. Professor Rostami is the Senior Vice President of Research & Development and Chief Scientific Officer at Certara. His mission is to ensure that the latest scientific advances in the field of biosimulation are incorporated into all of the drug development efforts by various pharmaceutical companies.

Certara combines its industry renowned pharmacometric and regulatory consultants with our vast software portfolio to provide services that focus on specific outcomes, therapeutic areas, regulatory milestones, and specific populations.